Skip to main content
Inventage Lab Inc. logo

Inventage Lab Inc. — Investor Relations & Filings

Ticker · 389470 ISIN · KR7389470006 KO Professional, scientific and technical activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country KR South Korea
Listing KO 389470

About Inventage Lab Inc.

https://www.inventagelab.com/m/en/

Inventage Lab Inc. is a biopharmaceutical company specializing in the development of advanced Drug Delivery Systems (DDS). The company's foundation is its proprietary microfluidics-based platform technology, Laminar-FluiDigm™, which is applied to pharmaceutical research and manufacturing. Inventage Lab operates two primary platforms: IVL-DrugFluidic® for developing and producing microsphere-based long-acting injectables, and IVL-GeneFluidic® for the formulation and manufacturing of Lipid Nanoparticles (LNPs) for nucleic acid and gene therapies. The company's pipeline is focused on treating chronic and refractory diseases, with key programs targeting androgenic alopecia (male pattern baldness) and Alzheimer's disease. Other development areas include drug re-discovery for conditions like rheumatic arthritis and multiple sclerosis, and collaborative projects for HIV treatments and mRNA-based therapies.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-05-08 Korean
투자판단관련주요경영사항(임상시험결과) (건강한 성인을 대상으로 IVL3003의 피하 또는 근육 주사와 ARICEPT®(도네페질) 정제 반복 투여 간 비교를 위한 공개, 탐색적, 연속적, 약동학, 단일용량상승 1상 임상시험)
Regulatory Filings Classification · 85% confidence The document is an ad-hoc material disclosure of clinical trial results (“투자판단 관련 주요경영사항(임상시험 결과)”), containing detailed trial design, safety and PK/PD data, and is published as a regulatory announcement. It is not an earnings release, quarterly report, investor presentation, or proxy statement, nor is it a simple notice that a report has been published. It fits the ‘general regulatory filings’ fallback category for miscellaneous mandatory disclosures. Therefore, it should be classified as Regulatory Filings (RNS).
2026-04-20 Korean
감자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 85% confidence The document is a corporate announcement detailing a capital reduction (감자) of a subsidiary (“종속회사의 주요경영사항”), specifying share counts before and after, reduction ratio, method, schedule, and regulatory references. This is an announcement of a change in the company’s capital structure (share reduction), not the full report itself. It fits the “Share Issue/Capital Change” category (SHA).
2026-04-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a standard insider ownership reporting form in Korean (“임원ㆍ주요주주 특정증권등 소유상황보고서”) detailing a company executive’s shareholdings, changes in holdings, transaction dates, quantities, and reasons. This fits the ‘Director’s Dealing’ category, which covers personal share transactions by company directors and executives (insider trades). It is not an announcement of a report nor a threshold notification, but the actual disclosure of insider trades. Therefore, the correct classification is DIRS.
2026-04-13 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.